Gregory S. Friedrichs

Gregory S. Friedrichs

Auto-generated profile, based on publicly available information

Gregory S. Friedrichs

Novartis Biomedical Research, 1 Health Plaza, East Hanover, NJ 07936-1080, USA

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 1994 in Cardiovascular Research
Verified
Journal Article
Closed access
PDF file
KKKenneth S Kilgore
Kenneth S Kilgore
GFGregory S Friedrichs
Gregory S Friedrichs
JHJonathon W Homeister
Jonathon W Homeister
BLBenedict R Lucchesi
Benedict R Lucchesi
Kenneth S Kilgore, Gregory S Friedrichs, Jonathon W Homeister, Benedict R Lucchesi; The complement system in myocardial ischaemia/reperfusion injury, Cardiovas

1 September 2019 in Journal of Pharmacological and Toxicological Methods
Verified
Journal Article
Closed access
SPSabina Paglialunga
Sabina Paglialunga
BMBruce H. Morimoto
Bruce H. Morimoto
MCMatthew Clark
Matthew Clark
GFGregory S. Friedrichs
Gregory S. Friedrichs

1 September 1996 in Journal of Cardiovascular Pharmacology and Therapeutics
Verified
Journal Article
Closed access
PDF file
MGMichael R. Gralinski
Michael R. Gralinski
EDEdward M. Driscoll
Edward M. Driscoll
GFGregory S. Friedrichs
Gregory S. Friedrichs
MDMichael R. DeNardis
Michael R. DeNardis
BLBenedict R. Lucchesi
Benedict R. Lucchesi
We determined if a single administration of heparin or nonanticoagulant N-acetylheparin could reduce myocardial injury resulting from a 90-minute occlusion of the left circumflex coronary artery (LCX) and 6 hours of reperfusion in the anesthetized canine. Heparin (2 mg/kg), N-acetylheparin (2 mg/kg), or vehicle, 0.9% sodium chloride (control), was administered intravenously to separate groups of animals 2 hours before LCX occlusion. To ensure parity of LCX ischemia, only animals with ischemic zone regional blood flow < 0.16 mL/min/g tissue were included in the final analysis. Hemodynamics did not differ among the three study groups. Infarct size as a percentage of the left ventricular area at risk was obtained for each group. Myocardial infarct size was 43.0 ± 3.9% in the vehicle, 28.8 ± 5.8% in the heparin (P < .05 vs vehicle) and 24.7 ± 4.6% (P < .05 vs vehicle) in the N-acetylheparin-treated animals. Pretreatment with heparin or its nonanticoagulant derivative, N-acetylheparin, provides significant protection to the regionally ischemic and reperfused canine myocardium independent of either plasma glycosaminoglycan concentration or alterations in the coagulation system.

1 January 1994 in Journal of Cardiovascular Pharmacology
Verified
Journal Article
Open access
GFGregory S. Friedrichs
Gregory S. Friedrichs
LCLiguo Chi
Liguo Chi
SBShawn C. Black
Shawn C. Black
PMPeter J. Manley
Peter J. Manley
BLBenedict R. Lucchesi
Benedict R. Lucchesi
We studied the electrophysiologic and anti-fibrillatory effects of the class III agent MS-551 in a rabbit isolated heart model in which ventricular fibrillation (VF) occurs reproducibly under conditions of hyp-oxia/reoxygenation in the presence of the ATP-dependent potassium channel opener, pinacidil. Ten minutes after MS-551 or vehicle administration, addition of pinacidil (1.25 μM) to the buffer was followed by a 12-min hypoxic period and 40-min reoxygenation. At a low concentration of MS-551 (1.0 μM), VF occurred in 5 of 6 hearts, the same incidence as in the control group (5 of 6). In contrast 0 of 6 hearts treated with 15 μM MS-551 developed VF (p < 0.05 vs. vehicle). Ventricular effective refractory period (VERP) was determined in a separate group of isolated hearts (n = 13). Pinacidil alone, during normoxic perfusion, decreased VERP 48 ± 11% (p < 0.05) 15 min after exposure. Five minutes of hypoxia alone also decreased VERP (57 ± 8%, p < 0.05). Under normoxic conditions, MS-551 increased ERP 31 ± 10% (p < 0.05 vs. baseline). VERP prolongation by MS-551 was reduced in the presence of pinacidil but remained 22 ± 6% (p < 0.05) above baseline. The results suggest that VERP shortening owing to pinacidil mediated ATP-dependent K+ channel opening is associated with development of VF in isolated heart. MS-551 attenuates the pinacidil-mediated decrease in VERP and prevents pinacidil + hypoxia-reoxygenation-induced VF. Because pinacidil and hypoxia open myocardial KATP channels, putatively decreasing VERP, MS-551 may exert its antifibrillatory effect through partial blockade of K+ATP channels

17 September 2024 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Closed access
GFG.S. Friedrichs
G.S. Friedrichs
MAM.M. Abernathy
M.M. Abernathy
DAD. Ackley
D. Ackley
MCM. Clark
M. Clark
JDJ.K. DaSilva
J.K. DaSilva
TWT.A. Wisialowski
T.A. Wisialowski

14 May 2020 in International Journal of Toxicology
Verified
Journal Article
Closed access
PDF file
SASimon Authier
Simon Authier
MAMatthew M. Abernathy
Matthew M. Abernathy
KCKrystle Correll
Krystle Correll
RCRay W. Chui
Ray W. Chui
JDJill Dalton
Jill Dalton
MPMichael K. Pugsley
Michael K. Pugsley
Introduction: The Safety Pharmacology Society (SPS) conducted a membership survey to examine industry practices related mainly to cardiovascular (CV) safety pharmacology (SP). Methods: Questions addressed nonclinical study design, data analysis methods, drug-induced effects, and conventional and novel CV assays. Results: The most frequent therapeutic area targeted by drugs developed by the companies/institutions that employ survey responders was oncology. The most frequently observed drug-mediated effects included an increased heart rate, increased arterial blood pressure, hERG (IKr) block, decreased arterial blood pressure, decreased heart rate, QTc prolongation, and changes in body temperature. Broadly implemented study practices included Latin square crossover study design with n = 4 for nonrodent CV studies, statistical analysis of data (eg, analysis of variance), use of arrhythmia detection software, and the inclusion of data from all study animals when integrating SP studies into toxicology studies. Most responders frequently used individual animal housing conditions. Responders commonly evaluated drug effects on multiple ion channels, but in silico modeling methods were used much less frequently. Most responders rarely measured the J-Tpeak interval in CV studies. Uncertainties relative to Standard for Exchange of Nonclinical Data applications for data derived from CV SP studies were common. Although available, the use of human induced pluripotent stem cell cardiomyocytes remains rare. The respiratory SP study was rarely involved with identifying drug-induced functional issues. Responders indicated that the study-derived no observed effect level was more frequently determined than the no observed adverse effect level in CV SP studies; however, a large proportion of survey responders used neither.